Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

TABLA

Financiado

Cerrado

Development and Commercialisation of Transbronchial Lung Ablation to Treat Lung...

Development and Commercialisation of Transbronchial Lung Ablation to Treat Lung Cancer Lung cancer is the most common cause of cancer deaths in the EU and worldwide with more than 0.4M people diagnosed each year. It has a dismal 5 year survival rate of just 18% and worldwide someone dies of lung cancer every 30 seco... ver más

31/05/2023

ENDOWAVE

4M€

Presupuesto del proyecto: 4M€

Líder del proyecto

ENDOWAVE LIMITED No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 6 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2023-05-31

EIC-FTI-2018-2020: Fast Track to Innovation (FTI)

I+D

Cerrada hace 6 años

0% 71% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

6 Participantes

ENDOWAVE

2.03M€ | Lider

SOLPLAST

343.71K€ | Participante

OLLSCOIL NA GAILLIMHE

79.56K€ | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

ENDOWAVE ENDObronchial microWAVE Ablation for the minimally invasive... 71K€ Cerrado

Go-Smart A Generic Open end Simulation Environment for Minimally Inva... 5M€ Cerrado

LASER OPTIMAL Laser Ablation SElectivity and monitoRing for OPTImal tuMor... 1M€ Cerrado

DRAIOCHT DRAIOCHT A low cost minimally invasive platform medical dev... 130K€ Cerrado

Selio System Development and commercialisation of a novel needle tract se... 4M€ Cerrado

PULMOSTENT Development Evaluation of a Viable Stent Device for the Tr... 4M€ Cerrado

Duración del proyecto: 38 meses Fecha Inicio: 2020-03-26
Fecha Fin: 2023-05-31

Líder del proyecto

ENDOWAVE LIMITED No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 4M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Lung cancer is the most common cause of cancer deaths in the EU and worldwide with more than 0.4M people diagnosed each year. It has a dismal 5 year survival rate of just 18% and worldwide someone dies of lung cancer every 30 seconds. The impact of the disease on public health is substantial with > 6M hospital admissions in Europe each year (>€18 billion in economic costs). Surgery has been shown to provide a curative solution, but only 20-30% of patients can undergo surgery due to co-morbidities. Endowave have developed a pioneering device, designed to destroy the targeted tumour in a single, minimally invasive intervention. The patented technology uses a flexible catheter system, that can be navigated through the patient’s airway to deliver targeted microwave heating to the tumour. This will enable physicians provide a curative treatment that can be delivered in an outpatient setting, improving patient outcomes and reducing costs to healthcare system. The global market opportunity for lung cancer exceeds €3.6 billion. Endowave has formed a consortium of leading companies that seeks to commercial Endowave’s technology and capture this market opportunity. The proposal is seeking funding to complete the final development of the microwave system, carry out clinical studies achieve regulatory approval. This will enable Endowave to enter the market, where we forecast revenues of €60 million by Year 5 based on conservative market penetration forecasts. This project will drive job generation in Endowave and consortium partners as sales volumes increase.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores